PeerView Live


Downloads / CME/CE/CPE Credit

Chair and Presenters

Robert L. Ferris, MD, PhD
Robert L. Ferris, MD, PhD
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
UC San Diego
San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California
Quynh-Thu Le, MD, FACR, FASTRO
Quynh-Thu Le, MD, FACR, FASTRO
Stanford University
Stanford, California


6:45 PM Welcome and Introduction: Immunotherapy and the Way Forward in SCCHN Management (Robert L. Ferris, MD)
  • Mapping the current (and changing) treatment landscape in HNC, along with audience views and practice patterns with immune treatment and radiotherapy
6:55 PM Understanding the Rapid Emergence of Immunotherapy in SCCHN: From Major Trials to Novel Combinations (Ezra Cohen, MD)
  • A look at the science supporting the integration of immune therapy in SCCHN, including evidence on immune- or targeted-immune combinations
7:25 PM Where Disciplines Intersect: Patient Voices & Practical Applications of Immunotherapy in SCCHN (Panel)
  • A panel-based look at patient perspectives and voices, and what the integration of immunotherapy with modalities such as radiation means for them
7:35 PM Immunotherapy and Radiotherapy: Pursuing Synergistic Modalities in SCCHN (Quynh-Thu Le, MD)
  • A practical look at what using immune treatment in conjunction with radiotherapy means for clinicians who treat HNC
8:05 PM Symposium Summary and Audience Q&A (Panel)
  • A synthesis of topics covered throughout the event and audience questions answered on HNC care and the integration of immuno- and radiotherapy
8:15 PM Adjourn

CME/CE/CPE Information

Activity Description & Educational Objectives

Treatment options for patients with squamous cell cancer of the head and neck (SCCHN), including recurrent/metastatic SCCHN, have expanded with the rapid integration of immunotherapy into modern oncology. In particular, checkpoint blockade has become an important component of multimodal head and neck cancer (HNC) care. Currently, researchers are attempting to answer the question of how exactly immune checkpoint blockade will pair with existing treatment, such as radiotherapy, in the HNC setting; and what this further integration of immune therapy will mean for patients with recurrent/metastatic or locally advanced HNC.

Join PeerView’s latest interactive live webcast, hear the patient’s perspective on the changing treatment landscape, and find out what experts think about the current role and future potential of immune checkpoint inhibitors—including as a partner with radiotherapy—in the modern management of HNC.

Upon completion of this activity, participants will be able to:

Target Audience

This activity has been designed to meet the educational needs of radiation, medical, and surgical oncologists, advanced practice nurses, pharmacists, and other clinicians involved in the management of patients with squamous cell cancer of the head and neck.

Nursing Education Purpose Statement

The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of squamous cell cancer of the head and neck.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the evaluation and request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon completion of the evaluation and request for credit at the end of the post-test and evaluation form.

For pharmacists, Medical Learning Institute, Inc. will accept your completed evaluation form up to 30 days following participation and will report your participation in this educational activity to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks of participation, you will receive a confirmation email and can then view your participation record at the NABP website:

Media: Live webcast
Release and Expiration Date: September 26, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity during the past 12 months.


Robert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
Pittsburgh, Pennsylvania


Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science
UC San Diego Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
La Jolla, California

Quynh-Thu Le, MD, FACR, FASTRO
Katharine Dexter McCormick & Stanley McCormick Memorial Professor
Professor and Chair
Department of Radiation Oncology
Stanford University
Stanford, California

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education


The information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.


Accreditation Council for Pharmacy Education The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-17-011-L01-P.


This CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.


This activity is supported through educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Collaboration Statement

This activity was developed in collaboration with the Head and Neck Cancer Alliance (HNCA).

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.